Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity

No abstract is available for this paper.

• Publication year

  2011

• Venue

  European journal of drug metabolism and pharmacokinetics

• Publication date

  2011-02-19

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1007/s13318-011-0024-2PMID 21336516
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design

  2009cited by this paper
• Antibodies as a Probe in Cytochrome P450 Research

  2009cited by this paper
• Trimethoprim and the CYP2C8*3 Allele Have Opposite Effects on the Pharmacokinetics of Pioglitazone

  2008cited by this paper
• CYP2C19 Inhibition: The Impact of Substrate Probe Selection on in Vitro Inhibition Profiles

  2008cited by this paper
• Understanding methadone metabolism: a foundation for safer use.

  2008cited by this paper
• Role of CYP2B6 in Stereoselective Human Methadone Metabolism

  2008cited by this paper
• Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes.

  2008cited by this paper
• CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.

  2008cited by this paper
• Evaluation of Fluorescence- and Mass Spectrometry—Based CYP Inhibition Assays for Use in Drug Discovery

  2008cited by this paper
• A Comparison of 2-Phenyl-2-(1-piperidinyl)propane (PPP), 1,1′,1″-Phosphinothioylidynetrisaziridine (ThioTEPA), Clopidogrel, and Ticlopidine as Selective Inactivators of Human Cytochrome P450 2B6

  2007cited by this paper
• CYP2A13 Metabolizes the Substrates of Human CYP1A2, Phenacetin, and Theophylline

  2007cited by this paper
• Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS.

  2007cited by this paper
• Determination of microsomal CYP2A6 activity by high performance liquid chromatography

  2007cited by this paper
• Inhibitory Effects of Neurotransmitters and Steroids on Human CYP2A6

  2007cited by this paper
• High-Throughput Radiometric CYP2C19 Inhibition Assay Using Tritiated (S)-Mephenytoin

  2007cited by this paper
• Progress Curve Analysis of CYP1A2 Inhibition: A More Informative Approach to the Assessment of Mechanism-Based Inactivation?

  2007cited by this paper
• Evaluation of 227 Drugs for In Vitro Inhibition of Cytochrome P450 2B6

  2006cited by this paper
• Inhibition of human cytochrome CYP 1 enzymes by flavonoids of St. John's wort.

  2006cited by this paper
• Cytochrome P450s and other enzymes in drug metabolism and toxicity

  2006cited by this paper
• GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS

  2006cited by this paper
• EVALUATION OF TIME-DEPENDENT CYTOCHROME P450 INHIBITION USING CULTURED HUMAN HEPATOCYTES

  2006cited by this paper
• Effect of Ginkgo biloba extract on procarcinogen-bioactivating human CYP1 enzymes: identification of isorhamnetin, kaempferol, and quercetin as potent inhibitors of CYP1B1.

  2006cited by this paper
• CYP2A13 expressed in human bladder metabolically activates 4‐aminobiphenyl

  2006cited by this paper
• Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate

  2006cited by this paper
• The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico.

  2006cited by this paper
• Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization.

  2006cited by this paper
• Enzyme Source Effects on CYP2C9 Kinetics and Inhibition

  2006cited by this paper
• Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5

  2006cited by this paper
• AUTOMATED ASSESSMENT OF TIME-DEPENDENT INHIBITION OF HUMAN CYTOCHROME P450 ENZYMES USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY ANALYSIS

  2005cited by this paper
• SELECTIVE INHIBITION OF HUMAN CYTOCHROME P4502C8 BY MONTELUKAST

  2005cited by this paper
• Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.

  2005cited by this paper
• Utility of recombinant cytochrome p450 enzymes: a drug metabolism perspective.

  2005cited by this paper
• The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects.

  2005cited by this paper
• Examination of 209 Drugs for Inhibition of Cytochrome P450 2C8

  2005cited by this paper
• EVALUATION OF TIME-DEPENDENT INACTIVATION OF CYP3A IN CRYOPRESERVED HUMAN HEPATOCYTES

  2005cited by this paper
• CYP1A1 genotype-selective inhibition of benzo[a]pyrene activation by quercetin.

  2005cited by this paper
• 5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.

  2005cited by this paper
• Metabolism and Disposition Kinetics of Nicotine

  2005cited by this paper
• PREDICTION OF CYP2C9-MEDIATED DRUG-DRUG INTERACTIONS: A COMPARISON USING DATA FROM RECOMBINANT ENZYMES AND HUMAN HEPATOCYTES

  2005cited by this paper
• Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine

  2004cited by this paper
• Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible.

  2004cited by this paper
• Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.

  2004cited by this paper
• Validated assays for human cytochrome P450 activities.

  2004cited by this paper
• Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.

  2004cited by this paper
• Validation of (-)-N-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes.

  2004cited by this paper
• Inhibitory Effects of the Monoamine Oxidase Inhibitor Tranylcypromine on the Cytochrome P450 Enzymes CYP2C19, CYP2C9, and CYP2D6

  2004cited by this paper
• Diversity of selective environmental substrates for human cytochrome P450 2A6: alkoxyethers, nicotine, coumarin, N-nitrosodiethylamine, and N-nitrosobenzylmethylamine.

  2003cited by this paper
• In vitro drug interactions of cytochrome p450: an evaluation of fluorogenic to conventional substrates.

  2003cited by this paper
• In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole.

  2003cited by this paper
• In vitro activation of 7-benzyloxyresorufin O-debenzylation and nifedipine oxidation in human liver microsomes

  2003cited by this paper
• Reaction phenotyping in drug discovery: moving forward with confidence?

  2003cited by this paper
• Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification.

  2003cited by this paper
• INTERACTION BETWEEN FIBRATES AND STATINS - METABOLIC INTERACTIONS WITH GEMFIBROZIL

  2003cited by this paper
• Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.

  2003cited by this paper
• Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions.

  2003cited by this paper
• The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity

  2003cited by this paper
• The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

  2003cited by this paper
• High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry.

  2003cited by this paper
• Drug Interactions of Paclitaxel Metabolism in Human Liver Microsomes

  2003cited by this paper
• Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol.

  2003cited by this paper
• Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids.

  2002cited by this paper
• Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively.

  2002cited by this paper
• Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.

  2002cited by this paper
• Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate.

  2002cited by this paper
• Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors.

  2002cited by this paper
• (+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19.

  2002cited by this paper
• Summary of information on human CYP enzymes: human P450 metabolism data

  2002cited by this paper
• Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole.

  2002cited by this paper
• Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach.

  2002cited by this paper
• Effects of fibrates on metabolism of statins in human hepatocytes.

  2002cited by this paper
• Detection of cytochrome P450 mRNA transcripts in prostate samples by RT‐PCR

  2001cited by this paper
• Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus.

  2001cited by this paper
• Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.

  2001cited by this paper
• A novel testosterone 6 beta-hydroxylase activity assay for the study of CYP3A-mediated metabolism, inhibition, and induction in vitro.

  2001cited by this paper
• In Vitro/in Vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans

  2001cited by this paper
• In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene.

  2001cited by this paper
• Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?

  2001cited by this paper
• Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential‐toward a consensus

  2001cited by this paper
• Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus.

  2001cited by this paper
• Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.

  2001cited by this paper
• Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro.

  2001cited by this paper
• Inhibition of cytochrome P450 2C9 activity in vitro by 5-hydroxytryptamine and adrenaline.

  2001cited by this paper
• A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry.

  2001cited by this paper
• Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors.

  2001cited by this paper
• Inhibition by ticlopidine and its derivatives of human liver cytochrome p450. Mechanism-based inactivation of CYP 2C19 by ticlopidine.

  2001cited by this paper
• Progesterone oxidation by cytochrome P450 2D isoforms in the brain.

  2001cited by this paper
• Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450

  2000cited by this paper
• Fluvoxamine-Clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism.

  2000cited by this paper
• Mechanism-based inactivation of cytochromes P450 2B1 and P450 2B6 by 2-phenyl-2-(1-piperidinyl)propane.

  2000cited by this paper
• Automated high throughput human CYP isoform activity assay using SPE-LC/MS method: application in CYP inhibition evaluation

  2000cited by this paper
• Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4.

  2000cited by this paper
• CYP2A6: a human coumarin 7-hydroxylase.

  2000cited by this paper
• The xenobiotic inhibitor profile of cytochrome P4502C8.

  2000cited by this paper
• In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.

  2000cited by this paper
• Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug–drug interactions

  2000cited by this paper
• Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid.

  2000cited by this paper
• Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro.

  2000cited by this paper
• Demonstration of mRNA for five species of cytochrome P450 in human bone marrow, bone marrow‐derived macrophages and human haemopoietic cell lines

  2000cited by this paper
• Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.

  2000cited by this paper
• Metabolic Drug Interactions

  2000cited by this paper

• Computational Insights Into New Portulaca oleracea Alkaloids as Potential SARS‐CoV‐2 PLpro Inhibitors

  2025cites this paper
• Cytochrome P450 reaction phenotyping: State of the art.

  2025cites this paper
• Breaking point: Systemic mastocytosis manifesting as severe osteoporosis

  2025cites this paper
• P24-26 In vitro metabolism of didecyldimethylammonium chloride in human hepatic cytochrome P450 enzymes

  2025cites this paper
• Rapid multichannel fluorescent probe assay for CYP450 inhibition screening and drug interaction monitoring

  2024cites this paper
• Ionic Liquid 1-Octyl-3-Methylimidazolium (M8OI) Is Mono-Oxygenated by CYP3A4 and CYP3A5 in Adult Human Liver

  2024cites this paper
• Paracetamol metabolism by endothelial cells - potential mechanism underlying intravenous paracetamol-induced hypotension.

  2024cites this paper
• Next-generation of BBQ analogues that selectively target breast cancer

  2024cites this paper
• Metabolic activation and cytochrome P450 inhibition of piperlonguminine mediated by CYP3A4.

  2024cites this paper
• MD investigation on the differences in the dynamic interactions between the specific ligand azamulin and two CYP3A isoforms, 3A4 and 3A5

  2024cites this paper
• In vitro metabolism of the emerging contaminant 6PPD-quinone in human and rat liver microsomes: Kinetics, pathways, and mechanism.

  2024cites this paper
• A Review of CYP-Mediated Drug Interactions: Mechanisms and In Vitro Drug-Drug Interaction Assessment

  2024cites this paper
• Lipid mediators generated by the cytochrome P450-Epoxide hydrolase pathway.

  2023cites this paper
• Interaction between Changan Granule and its main components in the plasma and CYP450 enzymes.

  2023cites this paper
• Cytochrome P450 2B6 and UDP-Glucuronosyltransferase Enzyme–Mediated Clearance of Ciprofol (HSK3486) in Humans: The Role of Hepatic and Extrahepatic Metabolism

  2023cites this paper
• A Novel Cytochrome P450 2E1 Inhibitor Q11 Is Effective on Lung Cancer via Regulation of the Inflammatory Microenvironment

  2023cites this paper
• The role of cytochrome P450 3A4-mediated metabolism in sorafenib and lapatinib hepatotoxicity.

  2023cites this paper
• The CYP2E1 inhibitor Q11 ameliorates LPS-induced sepsis in mice by suppressing oxidative stress and NLRP3 activation.

  2023cites this paper
• A Physiologically-Based Pharmacokinetic Model for Cannabidiol in Healthy Adults, Hepatically-Impaired Adults, and Children

  2023cites this paper
• Biological Activity and Stability of Aeruginosamides from Cyanobacteria

  2022cites this paper
• Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism

  2022cites this paper
• Phase I Metabolism of Pterostilbene, a Dietary Resveratrol Derivative: Metabolite Identification, Species Differences, Isozyme Contribution, and Further Bioactivation.

  2022cites this paper
• Distinct effects of form selective cytochrome P450 inhibitors on cytochrome P450-mediated monooxygenase and hydrogen peroxide generating NADPH oxidase.

  2022cites this paper
• EVALUATION OF ABCB1-PROTEIN INHIBITION PROSPECTIVENESS IN HEMATOENCEPHALIC BARRIER AS METHOD FOR INCREASING EFFICIENCY OF PHARMACOTHERAPY IN CEREBRAL ISCHEMIA

  2022cites this paper
• Characterizing and Quantifying Extrahepatic Metabolism of (−)-Δ9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, (±)-11-Hydroxy-Δ9-THC (11-OH-THC)

  2022influential citation
• Defining the Selectivity of Chemical Inhibitors Used for Cytochrome P450 Reaction Phenotyping: Overcoming Selectivity Limitations with a Six-Parameter Inhibition Curve-Fitting Approach

  2022cites this paper
• Pirfenidone 5-hydroxylation is mainly catalysed by CYP1A2 and partly catalysed by CYP2C19 and CYP2D6 in the human liver

  2021influential citation
• DDDT_A_323186 3661..3673

  2021cites this paper
• Effects of Avitinib on CYP450 Enzyme Activity in vitro and in vivo in Rats

  2021cites this paper
• In vitro enantioselective inhibition of the main human CYP450 enzymes involved in drug metabolism by the chiral pesticide tebuconazole.

  2021cites this paper
• CYP2C9 and 3A4 play opposing roles in bioactivation and detoxification of diphenylamine NSAIDs.

  2021cites this paper
• Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design.

  2021cites this paper
• Differential Contribution of Renal Cytochrome P450 Enzymes to Kidney Endothelial Dysfunction and Vascular Oxidative Stress in Obesity.

  2021cites this paper
• (–)-N-3-Benzylphenobarbital Is Superior to Omeprazole and (+)-N-3-Benzylnirvanol as a CYP2C19 Inhibitor in Suspended Human Hepatocytes

  2020cites this paper
• Impact of cytochrome P450 variation on meperidine N-demethylation to the neurotoxic metabolite normeperidine

  2020cites this paper
• CYP 2 C 19 inhibitor in suspended human hepatocytes

  2020influential citation
• Meloxicam methyl group determines enzyme specificity for thiazole bioactivation compared to sudoxicam.

  2020cites this paper
• In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine

  2020cites this paper
• Induction of proliferative and mutagenic activity by benzo(a)pyrene in PC-3 cells via JAK2/STAT3 pathway.

  2020cites this paper
• Main contribution of UGT1A1 and CYP2C9 in the metabolism of UR-1102, a novel agent for the treatment of gout

  2020cites this paper
• In vitro and in vivo human metabolism and pharmacokinetics of S‐ and R‐praziquantel

  2020cites this paper
• Application of Azamulin to Determine the Contribution of CYP3A4/5 to Drug Metabolic Clearance Using Human Hepatocytes

  2020cites this paper
• Evaluation of Erythromycin as a Tool to Assess CYP3A Contribution of Low Clearance Compounds in a Long-Term Hepatocyte Culture

  2020cites this paper
• Strong and Selective Inhibitory Effects of the Biflavonoid Selamariscina A against CYP2C8 and CYP2C9 Enzyme Activities in Human Liver Microsomes

  2020cites this paper
• Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death

  2020cites this paper
• Inhibition of human CYP1 enzymes by a classical inhibitor α‐naphthoflavone and a novel inhibitor N‐(3, 5‐dichlorophenyl)cyclopropanecarboxamide: An in vitro and in silico study

  2020cites this paper
• An in vitro toolbox to accelerate anti-malarial drug discovery and development

  2020cites this paper
• P450 enzymes-based metabolic interactions between monarch drugs and the other constituent herbs: A strategy to explore compatibility mechanism of Sangju-Yin.

  2019cites this paper
• CYP2C19 and 3A4 Dominate Metabolic Clearance and Bioactivation of Terbinafine Based on Computational and Experimental Approaches.

  2019cites this paper
• In vitro phase I metabolism of vinclozolin by human liver microsomes

  2019influential citation
• Characterization of Porcine Hepatic and Intestinal Drug Metabolizing CYP450: Comparison with Human Orthologues from A Quantitative, Activity and Selectivity Perspective

  2019cites this paper
• Structural Insights into the Interaction of Cytochrome P450 3A4 with Suicide Substrates: Mibefradil, Azamulin and 6′,7′-Dihydroxybergamottin

  2019cites this paper
• Drug induced liver injury: assessment of inter-individual variation in the balance of bioactivation and inactivation as risk factor

  2018influential citation
• Mediated luminescent properties of salts with 4-((1H-imidazol-1-yl)methyl)benzonitrile: Syntheses, crystal structures and properties

  2018cites this paper
• Characterized in Vitro Metabolism Kinetics of Alkyl Organophosphate Esters in Fish Liver and Intestinal Microsomes.

  2018cites this paper
• Targeting the Genetic and Molecular Role of ABCG2 Following Traumatic Brain Injury

  2018cites this paper
• Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3A‐catalysed hydroxylation by sulfaphenazole

  2018cites this paper
• Evaluation of Strategies for the Assessment of Drug–Drug Interactions Involving Cytochrome P450 Enzymes

  2018cites this paper
• Stereoselective in vitro metabolism of rhynchophylline and isorhynchophylline epimers of Uncaria rhynchophylla in rat liver microsomes

  2018influential citation
• Mechanisms of Drug Interactions I: Absorption, Metabolism, and Excretion

  2018cites this paper
• Bioactivation of 1-chloro-2-hydroxy-3-butene, an in vitro metabolite of 1,3-butadiene, by rat liver microsomes.

  2018cites this paper
• In vitro and cellular systems for the characterization of bioactivating and inactivating drug metabolizing enzymes in adverse drug reactions: Insights into amodiaquine idiosyncratic toxicity

  2018influential citation
• In vitro metabolism studies of natural products are crucial in the early development of medicines

  2017influential citation
• Preclinical evaluation of the potential for cytochrome P450 inhibition and induction of the selective ALK inhibitor, alectinib

  2017influential citation
• In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17β‐dihydroexemestane

  2017cites this paper
• Estimation of fractions metabolized by hepatic CYP enzymes using a concept of inter-system extrapolation factors (ISEFs) – a comparison with the chemical inhibition method

  2017cites this paper
• In Vitro-In Vivo Extrapolation of Metabolism- and Transporter-Mediated Drug-Drug Interactions-Overview of Basic Prediction Methods.

  2017cites this paper
• Rosiglitazone Metabolism in Human Liver Microsomes Using a Substrate Depletion Method

  2017cites this paper
• The pharmacogenomics of severe traumatic brain injury.

  2017cites this paper
• LKY-047: First Selective Inhibitor of Cytochrome P450 2J2

  2017influential citation
• Characterization of human cytochrome P450 mediated bioactivation of amodiaquine and its major metabolite N‐desethylamodiaquine

  2017cites this paper
• Characterization and pharmacogenetics of hepatic phase I exemestane metabolism

  2017cites this paper
• Cytochrome P450-mediated metabolism of the synthetic cannabinoids UR-144 and XLR-11.

  2016cites this paper
• Improvement of the chemical inhibition phenotyping assay by cross-reactivity correction

  2016cites this paper
• Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children

  2016cites this paper
• High body clearance and low oral bioavailability of alantolactone, isolated from Inula helenium, in rats: extensive hepatic metabolism and low stability in gastrointestinal fluids

  2016cites this paper
• Hydroxylation of 20-hydroxyvitamin D3 by human CYP3A4.

  2016cites this paper
• Metabolic interactions of magnolol with cytochrome P450 enzymes: uncompetitive inhibition of CYP1A and competitive inhibition of CYP2C

  2016cites this paper
• Constrained spheroids for prolonged hepatocyte culture.

  2016cites this paper
• An extensive cocktail approach for rapid risk assessment of in vitro CYP450 direct reversible inhibition by xenobiotic exposure.

  2016influential citation
• Interspecies differences in metabolism of deoxypodophyllotoxin in hepatic microsomes from human, monkey, rat, mouse and dog.

  2016cites this paper
• Development of mechanistic mathematical models for gene-mediated drug-drug interactions

  2016cites this paper
• Characterization of human cytochrome P450s involved in the bioactivation of tri-ortho-cresyl phosphate (ToCP).

  2015cites this paper
• Determining the IC50 Values for Vorozole and Letrozole, on a Series of Human Liver Cytochrome P450s, to Help Determine the Binding Site of Vorozole in the Liver

  2015cites this paper
• Diagnosing Biopharmaceutical Limitations

  2015cites this paper
• The guinea‐pig expresses functional CYP2C and P‐glycoprotein: further validation of its usefulness in drug biotransformation/transport studies

  2015cites this paper
• CYP450 Enzyme-Mediated Metabolism of TCAS and Its Inhibitory and Induced Effects on Metabolized Enzymes in Vitro

  2015cites this paper
• Simultaneous Screening of Activities of Five Cytochrome P450 and Four Uridine 5'- Diphospho-glucuronosyltransferase Enzymes in Human Liver Microsomes Using Cocktail Incubation and Liquid Chromatography-Tandem Mass Spectrometry

  2015cites this paper
• DMD063016 1137..1146

  2015influential citation
• Cytochrome P450 Isoforms in the Metabolism of Decursin and Decursinol Angelate from Korean Angelica.

  2015cites this paper
• Whatever Happened to the Epoxyeicosatrienoic Acid-Like Endothelium-Derived Hyperpolarizing Factor? The Identification of Novel Classes of Lipid Mediators and Their Role in Vascular Homeostasis

  2015influential citation
• Hepatocyte-Based Metabolism, Drug–Drug Interaction, and Toxicity Assays in Drug Discovery and Drug Development to Minimize Attrition

  2015cites this paper
• Modeling of interactions between xenobiotics and cytochrome P 450 ( CYP ) enzymes

  2015cites this paper
• Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism.

  2015cites this paper
• Modulation of Cytochrome P450 Activity by 18β‐Glycyrrhetic Acid and its Consequence on Buspirone Pharmacokinetics in Rats

  2015influential citation
• Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.

  2015cites this paper
• Alterations in Cerebral Xenobiotic-Metabolizing Enzymes in Iodine and / or Selenium Deficient Rats

  2015cites this paper
• Reaction Phenotyping: Advances in the Experimental Strategies Used to Characterize the Contribution of Drug-Metabolizing Enzymes

  2015cites this paper
• 1-Heteroaryl-3-phenoxypropan-2-ones as inhibitors of cytosolic phospholipase A₂α and fatty acid amide hydrolase: Effect of the replacement of the ether oxygen with sulfur and nitrogen moieties on enzyme inhibition and metabolic stability.

  2015cites this paper
• Danazol Inhibits Cytochrome P450 2J2 Activity in a Substrate-independent Manner

  2015influential citation